AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca’s latest clinical study, officially titled A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations, aims to evaluate the efficacy and safety of Dato-DXd combined with durvalumab and carboplatin against pembrolizumab with platinum-based chemotherapy in treating advanced non-small cell lung cancer (NSCLC) without actionable genomic alterations.
The study tests the experimental combination of Datopotamab Deruxtecan, Durvalumab, and Carboplatin, which are administered via intravenous infusion every three weeks. This combination is compared to the active comparator group receiving Pembrolizumab with histology-specific platinum-based chemotherapy, aiming to improve progression-free survival (PFS) and overall survival (OS) in NSCLC patients.
This Phase III study follows a randomized, open-label, parallel assignment design, focusing primarily on treatment. Participants are randomly allocated to either the experimental or active comparator group, with no masking involved, ensuring transparency in treatment administration.
The study commenced on December 29, 2022, with an active but not recruiting status. The primary completion and estimated study completion dates are yet to be announced, with the last update submitted on July 1, 2025. These dates are crucial for tracking the study’s progress and potential market entry timelines.
The outcome of this study could significantly impact AstraZeneca’s stock performance, as positive results may enhance investor confidence and market position in the competitive oncology sector. The study’s findings could influence the treatment landscape for NSCLC, potentially affecting competitors offering similar therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.